Drugs / Blarcamesine
Blarcamesine
also known as
ANAVEX2-73 · AE37 · AE-37 hydrochloride · ANA001-HCl · Anavex · ANAVEX 2-73 HYDROCHLORIDE · Blarcamesina · BLARCAMESINE HYDROCHLORIDE
Small molecule targets SIGMAR1 via activation
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 27 trials | ||||||
| Phase 2 | NCT04575259 | Oct 2019 → May 2022 | Parkinson disease | Anavex Life Sciences Corp. | Completed | No outcome recorded |
| Phase 2 | NCT04024800 | May 2019 → Jun 2023 | triple-negative breast carcinoma | NuGenerex Immuno-Oncology | Unknown | No outcome recorded |
| Phase 2 | NCT03758924 | Feb 2019 → Oct 2020 | Rett syndrome | Anavex Life Sciences Corp. | Completed | No outcome recorded |
| Phase 2 | NCT03774459 | Jul 2018 → Sep 2020 | Parkinson disease | Anavex Life Sciences Corp. | Completed | No outcome recorded |
| Phase 2 | NCT02756858 | Mar 2016 → Nov 2020 | Alzheimer disease | Anavex Life Sciences Corp. | Completed | No outcome recorded |
| Phase 2 | NCT02244541 | Dec 2014 → Nov 2015 | Alzheimer disease | Anavex Life Sciences Corp. | Completed | No outcome recorded |
| Phase 2 | NCT00524277 | Jan 2007 → Dec 2014 | breast cancer | San Antonio Military Medical Center | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04304482 | Jul 2020 → Jun 2023 | Rett syndrome | Anavex Life Sciences Corp. | Completed | No outcome recorded |
| Phase 2/3 | NCT04314934 | Oct 2019 → Jun 2024 | Alzheimer disease | Anavex Life Sciences Corp. | Completed | No outcome recorded |
| Phase 2/3 | NCT03790709 | Jul 2018 → Jun 2022 | Alzheimer disease | Anavex Life Sciences Corp. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03941444 | May 2019 → Sep 2021 | Rett syndrome | Anavex Life Sciences Corp. | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Blarcamesine | “Blarcamesine (ANAVEX2-73), a selective sigma-1 receptor (SIGMAR1) agonist, was studied in a 57-week Phase 2a trial (NCT02244541).” PMID 32318621 ↗ Apr 2020 |
| Known as | AE-37 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297224 ↗ |
| Known as | AE37 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04024800 ↗ |
| Known as | ANA001-HCl | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297224 ↗ |
| Known as | Anavex | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297224 ↗ |
| Known as | ANAVEX 2-73 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297224 ↗ |
| Known as | ANAVEX2-73 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03790709 ↗ |
| Known as | Blarcamesina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297224 ↗ |
| Known as | BLARCAMESINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297224 ↗ |
| Action | Activate | “a selective sigma-1 receptor (SIGMAR1) agonist” PMID 32318621 ↗ Apr 2020 |
| Modality | Vaccine | “AE37 is a promising primarily CD4(+) T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials.” PMID 21895539 ↗ Sep 2011 |
| Route | Intravenous | “In one period the intravenous (iv) form will be given and in the other period the oral dose will be given.” NCT02244541 ↗ |
| Route | Oral | “In one period the intravenous (iv) form will be given and in the other period the oral dose will be given.” NCT02244541 ↗ |
| Target | SIGMAR1 | “a selective sigma-1 receptor (SIGMAR1) agonist” PMID 32318621 ↗ Apr 2020 |